When it comes to lobbying and the pharmaceutical industry, apparently you can never have too many voices.
The Center for Responsive Politics says the pharmaceutical industry spent $150 million on lobbying in 2007.
The Pink Sheet trade publication says that Frazer’s Cephalon Inc. and Chadds Ford’s Endo Pharmaceuticals Holdings Inc. have teamed with five other drug makers to form America’s Specialty Medicines Companies.
Cephalon’s vice president of public affairs Sheryl Williams confirms the companies have been talking for months, but that right now it’s an “informal working group.”
I can’t imagine that Washington really needs another group calling on Congress on behalf of the drug industry.
After all, the Pharmaceutical Research & Manufacturers Association, one of the most powerful trade associations, spent $22.7 million on lobbying last year.
And the Biotechnology Industry Organization, which has become the biggest advocate for biotech companies, spent $7.2 million.
But Williams said Cephalon and the other six companies involved in this working group are not giants like those in Big Pharma. (The other members are Celgene, Cubist, Millennium, Purdue and Sepracor.) They’re also not development-stage firms working on biologics.
Each of these seven has at least one or two drugs that provide most of their revenue, Williams said. As a result, their situation can be more tenuous than a Big Pharma company that can rely on dozens of products, including the billion-dollar-selling blockbusters.
She said the group sees its concerns as different from those of Big Pharma and traditional biotech even if it hasn’t been able to articulate exactly what it will stand for. The companies just know that when it comes to federal legislation “it’s not one size fits all,” Williams said.
Maybe these companies are what parents say about teenagers: They’re at an awkward age. Too old to play with the kids, but not old enough to hang with the adults.
Still, let’s hope they don’t start hanging out on the corners outside the Capitol.
- Philly Skyline
- Delaware Business Blog
- PlanPhilly
- Changing Skyline
- Dangerously Awesome
- Greater Philly chamber
- Consumer Inq
- Freakonomics
- Oddly Enough
- Philly PharmaBio Blog
- Physicians News Digest
- Pharmalot
- BloggingStocks
- 10Q Detective
- PhiLAWdelphia
- Delaware Corp Litigation Blog
- Philadelphia Forward
- Great Expectations
- SEPTA Watch
- PhillyFuture
- Comcast Must Die
- Philly Geeks
- Philadelphia Tech News
- Broadband Reports
- Phila Road Warrior
- February
- January
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
- October 2010
- September 2010
- August 2010
- July 2010
- June 2010
- May 2010
- April 2010
- March 2010
- February 2010
- January 2010
- December 2009
- November 2009
- October 2009
- September 2009
- August 2009
- July 2009
- June 2009
- May 2009
- April 2009
- March 2009
- February 2009
- January 2009
- December 2008
- November 2008
- October 2008
- September 2008
- August 2008
- July 2008
- June 2008
- May 2008
- April 2008
- March 2008
- February 2008







Mike Armstrong, a business editor and writer for nearly two decades, is the Inquirer's business columnist and PhillyInc blog editor. Contact Mike 